BIOTECH ASSISTANT / FIELD NOTES

Model-Informed Decision Making from Drug Discovery to Reimbursement: A Roadmap for Clinical Pharmacology in Value-Based Healthcare

Academic source · The Journal of Clinical Pharmacology

Source published: · Event / reporting date: 2026-08-20

Site published: 2026-11-04 · Updated: 2026-11-04

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

What the paper reports

This commentary proposes a lifecycle approach to model-informed decision-making, from discovery and dose selection to regulatory evaluation and reimbursement. It discusses quantitative methods, patient-relevant outcomes, and real-world data, alongside challenges in integration, transparency, and stakeholder acceptance. It is a conceptual roadmap, not a prospective validation of one modeling strategy.

Why this paper is included

Helps frame modeling around decisions and the evidence needed to support them.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Clinical Pharmacology & Model-Informed Development

Related updates

Ethris / GlobeNewswire

Ethris reports exploratory antiviral and exposure-response signals for nasal ETH47 in asthma

Ethris reported topline results from a randomized Phase 2a rhinovirus-challenge study involving 50 adults with asthma. A single nasal dose of ETH47, an interferon-lambda-encoding mRNA candidate, produced local expression and lower day-two viral load. Symptom improvements were described as numerical trends; exposure-response subgroup findings remain exploratory, without established clinical efficacy.

Labcorp

Labcorp poster describes a shared free-IgE assay for a head-to-head clinical study

Labcorp's CBF 2026 poster summary describes a unified serum free-IgE assay supporting comparison of two IgE-targeting drug candidates, including a marketed comparator. The team evaluated assay conditions that can disturb drug–IgE equilibrium and reports establishing a fit-for-purpose method. The public summary does not identify the therapies or provide numerical validation metrics; it is a conference report.

Clinical Pharmacology & Therapeutics / PMC

Review identifies higher patient exposure for some drugs in chronic inflammation

Based on the article abstract, a review of 20 approved small-molecule medicines for selected chronic inflammatory diseases found more than 25% higher exposure in patients for five medicines, using reported population pharmacokinetic analyses. The authors highlight CYP3A4 and CYP2C19 metabolism. This cross-drug review supports risk assessment, not automatic dose changes for individual patients.

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗
AI assistant ↗